Christopher A. Viehbacher - 01 Dec 2025 Form 4 Insider Report for BIOGEN INC. (BIIB)

Role
President and CEO, Director
Signature
/s/ Wendell Taylor, attorney-in-fact for Christopher A. Viehbacher
Issuer symbol
BIIB
Transactions as of
01 Dec 2025
Net transactions value
-$605,163
Form type
4
Filing time
03 Dec 2025, 16:42:56 UTC
Previous filing
10 Feb 2025
Next filing
10 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Viehbacher Christopher President and CEO, Director BIOGEN INC., 225 BINNEY, CAMBRIDGE /s/ Wendell Taylor, attorney-in-fact for Christopher A. Viehbacher 03 Dec 2025 0001774478

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BIIB Common Stock Options Exercise $0 +7,040 +55% $0.000000 19,847 01 Dec 2025 Direct
transaction BIIB Common Stock Tax liability $605,163 -3,404 -17% $177.78 16,443 01 Dec 2025 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BIIB Restricted Stock Unit Options Exercise $0 -7,040 -100% $0.000000 0 01 Dec 2025 Common Stock 7,040 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each Restricted Stock Unit ("RSU") represents the right to receive, at settlement, one share of common stock.
F2 Each RSU vested on the third anniversary of the grant date of December 1, 2022.